Hutchmed Completes Enrollment for the P-II/III Trial for Fruquintinib + Sintilimab to Treat Renal Cell Carcinoma in China
Shots:
- Hutchmed reports the completion of enrollment for P-II/III (NCT05522231) trial of fruquintinib with sintilimab for 2L treatment of renal cell carcinoma patients (n=234)
- The P-II/III study evaluates the safety & efficacy of fruquintinib + sintilimab vs monotx. (axitinib or everolimus). The 1EP of the study includes PFS & 2EP is ORR, DCR, OS, DoR & time of response
- Fruquintinib selectively inhibits VEGFR-1, -2, & -3 orally, crucial for blocking tumor angiogenesis. It was designed to enhance selectivity, ensure high drug exposure, sustained target inhibition, and flexibility for potential combination therapy
Ref: HUTCHMED | Image: HUTCHMED
Related News:- HUTCHMED Reports the NDA Submission of Fruquintinib for Previously Treated Metastatic Colorectal Cancer in Japan
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Kritika is a content writer at PharmaShots. She is interested in covering recent innovations from the pharma & MedTech industry. She covers news related to Product approvals, clinical trial results, and updates. She can be contacted at connect@pharmashots.com.
